Alpha-1 Antitrypsin Deficiency Treatment Market Outlook 2031:
The Alpha-1 antitrypsin Deficiency Treatment Market size was valued at USD 1.49 Billion in 2022 and is projected to reach USD 3.78 Billion by 2031, expanding at a CAGR of 10.9% during the forecast period 2023 - 2031. Alpha-1 antitrypsin deficiency or AAT deficiency, is a genetic disorder characterized by a lack of AAT protein in the body. It is essential for the lungs and liver to defend themselves against the harmful effects of other proteins.
The deficiency of AAT can develop liver cirrhosis, chronic obstructive pulmonary disease (COPD), or emphysema. Tests such as genetics and blood tests can diagnose this disease. Medicines such as bronchodilators and corticosteroids, which can be injected intravenously or inhaled, are frequently used for treatment methods such as augmentation therapy, pulmonary rehabilitation, and oxygen therapy.
Alpha-1 Antitrypsin Deficiency Treatment Market Trends, Drivers, Restraints, and Opportunities:
- Increasing improvement in the diagnosis of alpha1-antitrypsin deficiency is estimated to boost the growth of the market.
- Various technological advancements in the diagnostic methods and the development of innovative processes for the production & purification of AAT are acting as growth-inducing factors for the market.
- High prevalence of chronic respiratory diseases across the world is the major driver for the growth of the market.
- Widespread adoption of augmentation therapy is providing a thrust to the market growth.
- Increasing cost of drugs can create challenges for the market growth.
- Stringent regulations along with less availability of plasma fractionation capacity can restrain the growth of the market.
- Increasing demand for deficiency treatment, improving economic scenario, increasing awareness regarding alpha1-antitrypsin deficiency, surging investment for the development of advanced and technical products are some of the factors that can accelerate the growth.
- The PlasmaTech SDF (salt diafiltration) process is a plasma-based platform was introduced for mass production of orphan protein therapeutics such as alpha-1 antitrypsin Thus, such innovation can create lucrative opportunities for the industry players.
Scope of Alpha-1 Antitrypsin Deficiency Treatment Market Report
The report on alpha-1 antitrypsin deficiency treatment market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
Attributes
|
Details
|
Report Title
|
Alpha-1 Antitrypsin Deficiency Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast
|
Base Year
|
2022
|
Historic Data
|
2016 & 2021
|
Forecast Period
|
2023–2031
|
Segmentation
|
Treatment Types (Augmentation Therapy, Bronchodilators, Corticosteroids, Oxygen Therapy, and Others), Route of Administration (Parental, Inhalation, and Oral), End-users (Hospitals, Specialty Clinics, and Others)
|
Regional Scope
|
Asia Pacific, North America, Europe, Latin America, and Middle East & Africa
|
Report Coverage
|
Market scope, analysis, share, competitive analysis, growth facts, restraints, opportunities, and revenue forecast
|
Key Players Covered in the Report
|
Grifols, S.A., Kamada Pharmaceuticals., CSL, Arrowhead Pharmaceuticals, Inc., CHIESI Farmaceutici S.p.A., AstraZeneca, Henry Schein, Inc., Healthy Life Pharma Private Limited., Hovione, Switzer Life science Pvt. Ltd., Cyndea Pharma, Anuh Pharma Ltd., Cipla Inc., Pfizer Inc., Anantco Enterprises Pvt. Ltd.
|
Alpha-1 Antitrypsin Deficiency Treatment Market Segment Insights
Augmentation therapy segment is projected to hold significant market share
In the terms of treatment types, the market can be divided into augmentation therapy, bronchodilators, corticosteroids, oxygen therapy and others. The augmentation therapy segment accounted for a major market share in 2020, and is expected to continue to grow at a robust rate during the forecast period. This is due to high acceptance of the therapy in developed regions such as the US and Europe.
Inhalation segment is anticipated to account for a substantial share
Based on route of administration, the alpha-1 antitrypsin deficiency treatment market can be segregated into parental, inhalation and oral. The inhalation segment is estimated to hold a substantial market during the forecast period owing to increasing focus on R&D for developing inhalation formulation of existing alpha-1 antitrypsin.
Hospital segment accounted for a major market share in 2020
On the basis of end-users, the market can be divided into hospitals, specialty clinics, and others. The hospitals segment dominated the global market in 2020 due to rising patients of COPD and presence of favourable reimbursement programs in developed and emerging countries.
North America to dominates the market
In terms of regions, the alpha-1 antitrypsin deficiency treatment market can be categorized as Asia Pacific, North America, Europe, Latin America, and the Middle East & Africa.
North America is estimated to dominate the market in 2020 due to growing prevalence of alpha1-antitrypsin deficiency along with increasing healthcare expenditure, while the market in Asia Pacific is expected to grow at a robust CAGR during the forecast period due to increasing initiatives by the government to control genetic disorders and improvement in diagnostics techniques.
Segments
By Treatment Types
- Augmentation Therapy
- Bronchodilators
- Corticosteroids
- Oxygen Therapy
- Others
By Route of Administration
By End-users
- Hospitals
- Specialty Clinics
- Others
By Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
By Key Players
- Grifols, S.A.
- Kamada Pharmaceuticals.
- CSL
- Arrowhead Pharmaceuticals, Inc.
- CHIESI Farmaceutici S.p.A.
- AstraZeneca
- Henry Schein, Inc.
- Healthy Life Pharma Private Limited.
- Hovione
- Switzer Life science Pvt. Ltd.
- Cyndea Pharma
- Anuh Pharma Ltd.
- Cipla Inc.
- Pfizer Inc.
- Anantco Enterprises Pvt. Ltd.
Competitive Landscape
Key players in the alpha-1 antitrypsin deficiency treatment market are Grifols, S.A., Kamada Pharmaceuticals., CSL, Arrowhead Pharmaceuticals, Inc., CHIESI Farmaceutici S.p.A., AstraZeneca, Henry Schein, Inc., Healthy Life Pharma Private Limited.,
Hovione, Switzer Life science Pvt. Ltd., Cyndea Pharma, Anuh Pharma Ltd., Cipla Inc., Pfizer Inc., Anantco Enterprises Pvt. Ltd., among other domestic and global players.These players engage in mergers & acquisitions, collaborations, agreements, and partnerships to strengthen their geographical presence.